Zentalis Pharmaceuticals Files 8-K Report
Ticker: ZNTL · Form: 8-K · Filed: Sep 16, 2024 · CIK: 1725160
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: ZNTL
TL;DR
Zentalis filed an 8-K, likely with updates. Keep an eye out for details.
AI Summary
On September 16, 2024, Zentalis Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and Other Events, along with Financial Statements and Exhibits. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing indicates Zentalis Pharmaceuticals is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided excerpt is a standard SEC filing notification and does not contain specific financial or operational risks.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Registrant
- 0001725160-24-000161 (filing_id) — Accession Number
- September 16, 2024 (date) — Report Date
FAQ
What is the primary purpose of this 8-K filing?
The filing is for a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
What is the exact date of the earliest event reported?
The earliest event reported is September 16, 2024.
What is the company's Central Index Key (CIK)?
The company's CIK is 0001725160.
What is Zentalis Pharmaceuticals' business address?
The business address is 10275 Science Center Drive, Suite 200, San Diego, CA 92121.
What is the SEC file number for Zentalis Pharmaceuticals?
The SEC file number is 001-39263.
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-09-16 07:02:19
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share ZNTL The Nasdaq Glo
Filing Documents
- zntl-20240916.htm (8-K) — 34KB
- zntlfdaliftspartialclinica.htm (EX-99.1) — 14KB
- zenalis_primarybluenavy.jpg (GRAPHIC) — 67KB
- 0001725160-24-000161.txt ( ) — 283KB
- zntl-20240916.xsd (EX-101.SCH) — 2KB
- zntl-20240916_def.xml (EX-101.DEF) — 4KB
- zntl-20240916_lab.xml (EX-101.LAB) — 26KB
- zntl-20240916_pre.xml (EX-101.PRE) — 16KB
- zntl-20240916_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 16, 2024, Zentalis Pharmaceuticals, Inc. (the "Company") issued the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Current Report") and incorporated herein by reference. The information contained in Item 7.01 of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.
01 Other Events
Item 8.01 Other Events. On June 18, 2024, the Company disclosed that the U.S. Food and Drug Administration ("FDA") had placed certain of the Company's clinical studies of azenosertib on partial clinical hold. On September 16, 2024, the Company announced that the FDA has lifted the partial clinical hold and that the FDA has cleared the Company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Press Release issued on September 16, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENTALIS PHARMACEUTICALS, INC. Date: September 16, 2024 By: /s/ Kimberly Blackwell, M.D. Kimberly Blackwell, M.D. Chief Executive Officer